Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials

Affiliations

¹ Medical University of South Carolina, Charleston, SC, USA.
² MAPS Public Benefit Corporation, 1115 Mission St, Santa Cruz, CA, USA. alli@mapsbcorp.com.
³ MAPS Public Benefit Corporation, 1115 Mission St, Santa Cruz, CA, USA.
⁴ Private Practice, Charleston, SC, USA.
⁵ University of British Columbia-Okanagan, Kelowna, BC, Canada.
⁶ Stanford School of Medicine, Stanford University, Stanford, CA, USA.
⁷ Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, USA.

Michael C Mithoefer et al. Psychopharmacology (Berl). 2024 Nov.

. 2024 Nov;241(11):2405.

doi: 10.1007/s00213-024-06666-x.

¹ Medical University of South Carolina, Charleston, SC, USA.
² MAPS Public Benefit Corporation, 1115 Mission St, Santa Cruz, CA, USA. alli@mapsbcorp.com.
³ MAPS Public Benefit Corporation, 1115 Mission St, Santa Cruz, CA, USA.
⁴ Private Practice, Charleston, SC, USA.
⁵ University of British Columbia-Okanagan, Kelowna, BC, Canada.
⁶ Stanford School of Medicine, Stanford University, Stanford, CA, USA.
⁷ Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, USA.

No abstract available

Retraction of

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. Mithoefer MC, et al. Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. Psychopharmacology (Berl). 2019. Retraction in: Psychopharmacology (Berl). 2024 Nov;241(11):2405. doi: 10.1007/s00213-024-06666-x. PMID: 31065731 Free PMC article. Retracted. Clinical Trial.